Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/19/2013

an additional 30%, raising the price to $3,850 per vial, effective January 16, 2013.

Cost of goods sold increased $6.4 million to $9.7 million for the three-month period ended December 31, 2012, from $3.3 million for the three-month period ended December 31, 2011. For the three-month periods ended December 31, 2012 and 2011, we recorded charges of $7.9 million and $1.3 million, respectively, against operations, resulting in a year-over-year increase in cost of goods sold of $6.6 million.  The increase in the charges to cost of goods sold related to raw material inventory and commitments, and finished goods inventory that we do not believe we will be able to sell through to commerce prior to expiration, resulting from lower sales demand forecasts for KRYSTEXXA in future years. 

Research and development expenses decreased $2.0 million, or 27%, to $5.5 million for the three-month period ended December 31, 2012, from $7.5 million for the three-month period ended December 31, 2011. The decrease is primarily the result of reduced spending on post marketing commitment costs partially offset by increased costs to support our marketing authorization application, or MAA, filing for KRYSTEXXA in the EU.

Selling, general and administrative expenses decreased $11.6 million, or 41%, to $16.5 million for the three-month period ended December 31, 2012, from $28.1 million for the three-month period ended December 31, 2011. The decrease in expense is mainly due to a reduction in selling and promotion costs for KRYSTEXXA compared to commercial launch year-related expenses in 2011 and cost containment activities resulting from our reorganization plan initiated in July 2012.

Interest expense on our debt increased $2.4 million, or 53%, to $6.9 million for the three-month period ended December 31, 2012, from $4.5 million for the three-month period ended December 31, 2011. Interest expense for the three-month period ended December 31, 2012 refl
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
4. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
5. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
6. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
7. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
8. AVANIR Pharmaceuticals To participate in two conferences in March
9. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
10. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... TRIANGLE PARK, N.C. , July 14, 2014 ... focused on cloud-based drug design and development, announced ... development program. The company has been granted supercomputing ... of multiple parasitic targets.  Through ... the Argonne Leadership Computing Facility (ALCF), researchers at ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Inc., the,leading developer of stents designed for the ... has closed a $14 million Series,C round of ... Venture,Partners joined with Spray Venture Partners in the ... RiverVest have been appointed to the Tryton,Board of ...
... blood pressure of elderly patients could cut their total,mortality ... by a third,according to a new study presented today ... simultaneously in the New England,Journal of Medicine., LONDON, ... Elderly Trial (HYVET), which is co-ordinated by scientists from,Imperial ...
... discover and develop ... SAN FRANCISCO, March 31 The Immune Tolerance Institute,Inc. ... a Center for Critical Path Immunology to investigate the role ... be managed by,ITI and located initially at Beckman Coulter,s Cellular ...
Cached Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 2The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 3
(Date:7/14/2014)... German . , ... development. One classical example is the sequential and rhythmic ... that has been linked to the ticking of an ... now, this patterning process was thought to be determined ... periodically trigger new segment formation. However, this week in ...
(Date:7/14/2014)... MedNet Solutions , a global ... management systems, is pleased to announce that ... on software-as-a-service (SaaS) and Internet-based businesses, has made ... funding, representing the first major outside financing in ... the ongoing growth and development of both MedNet ...
(Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
... New evidence suggests that the risk of HIV transmission ... According to a study published in the April ... available online, early infection accounted for nearly half of ... province of Quebec, Canada. , Bluma Brenner, PhD, and ...
... Turn up the white noise, says a team of ... the benefits of noise. Their findings could lead to ... an assistant professor of computer science, Joseph Martin, a ... of biology, are working together to explain the biological ...
... no two brains are alike, they can display a ... sensory input. Scientists at the Max Planck Institute for ... mathematical method to design networks from neural cells which ... their method will assist them in getting closer to ...
Cached Biology News:Risk of HIV transmission highest early in infection 2Noise echoes in cell communications 22 brains -- 1 thought 22 brains -- 1 thought 3
...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
... Beagle serum is collected from fasted Beagle canines ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
... cDNA Purification Kit is designed to purify double-stranded ... cDNA synthesis and PCR. The process is simple ... to 3 g can be efficiently purified and ... 1) DNA is bound to the Microfilter Cartridge ...
Biology Products: